Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;11(1):95-102.
doi: 10.1016/j.iccl.2021.09.010.

Caval Valve Implantation

Alexander Lauten  1 , Henryk Dreger  2 , Michael Laule  2 , Karl Stangl  2 , Hans R Figulla  3 , Marvin H Eng  4
Affiliations
Review

Caval Valve Implantation

Alexander Lauten et al. Interv Cardiol Clin. 2022 Jan.

Abstract

Transcathetertherapy has expanded the treatment options for patients with heart valve disease. Interventional therapy for aortic, mitral, and pulmonic valve disease is well established; however, catheter-based approaches to tricuspid regurgitation (TR) are still in early stages of development. For some of the interventional concepts to TR, including the edge-to-edge-repair, transcatheter annuloplasty, the tricuspid spacer, and caval valves, procedural feasibility and favorable early clinical outcome have been demonstrated in small compassionate case series. This article reviews the pathophysiological background and current evidence for caval valve implantation and examines the potential role of this approach for the treatment of severe TR.

Keywords: Caval valve implantation; Functional tricuspid regurgitation; Right heart failure; Tricuspid valve insufficiency; Tricuspid valve regurgitation.

PubMed Disclaimer

Conflict of interest statement

Disclosure A. Lauten: Consultant to P&F TricValve, receives research support from Edwards Lifesciences. H. Dreger reports grants from Edwards Lifesciences. H.R. Figulla is a consultant to P&F TricValve and the founder of JenaValve; K. Stangle reports grants from Edwards Lifesciences and speaker and proctor fees from Abbott, Edwards Lifesciences and Medtronic. M. Laule reports grants from Edwards Lifesciences and Berlin Institute of Health and speaker and proctor fees from Abbott, Edwards Lifesciences, and Medtronic. Marvin H. Eng is a proctor for Edwards Lifesciences and Medtronic.

Publication types

LinkOut - more resources